MC² Experience’s Post

From what I know Diabetes Type 2 can be reversed if the patient looses enough weight, so to me it seems that GLP-1 agonist drugs are enough. For more info, please read the article.

The latest episode of Pharmland is out now! From blood sugar control to cardiovascular protection, learn how GLP-1 medications are transforming treatment for patients with #diabetes. J Bradley Nelson, Thomas Davies, and Langley Kyle do an amazing job of covering the current state of these medications, including how plan sponsors can manage their increasing popularity and consequent shortages. Check out the full episode below! #Pharmacy #GLP1

FDA Approves First Non-Prescription Medical-Grade Pulse Oximeter for Advanced Respiratory Monitoring Masimo has received clearance from the FDA for their over-the-counter fingertip pulse oximeter, MightySat Medical. It is the first device of its kind available to consumers without a prescription and offers the same technology used by hospitals. Pulse oximeters are vital tools for individuals with respiratory conditions, providing accurate assessments of oxygen saturation levels. MightySat Medical addresses challenges faced by conventional pulse oximeters, delivering reliable measurements across diverse patient populations. Its availability instills confidence and empowers patients and healthcare providers to make informed decisions. However, it is important to consult a healthcare professional for treatment decisions. For more details please click the link! https://lnkd.in/d8pcYEbw #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

FREE WEBCAST TODAY: GLP-1 drugs like Ozempic and Wegovy are not just helping with Type 2 diabetes, but also reshaping weight loss management. The spike in prescriptions is now driving nearly 10% of total prescription costs for employers. Want to know how this impacts your organization's healthcare spend? Join our webinar at 1 p.m. ET today (Sept. 19) to dive deeper into the numbers and trends. Register here: https://lnkd.in/gcYsq3js

Did you get your fill of #pharmacynews this week? Take the #RxRoundup quiz of the week and test your knowledge about the latest stories published by the Drug Topics team from February 25 to March 1. #Pharmacy #QuizOfTheWeek https://lnkd.in/eZ5hesjz

✨ To address the ongoing challenges surrounding the shortage of GLP-1 medications, Ro, a direct-to-patient healthcare company, has launched the GLP-1 Supply Tracker, an innovative tool designed to provide patients with real-time insights and automated alerts on GLP-1 drug availability. The GLP-1 shortage — which has impacted access to popular weight loss and diabetes management drugs like Wegovy and Ozempic — has left many patients scrambling to find their necessary medications. Ro's new GLP-1 Supply Tracker aims to alleviate this burden by empowering patients with the information they need. #HealthcareInnovation #HealthTech #GLP1 #PatientCare #MedicationManagement #HealthSolutions #DigitalHealth #WellnessJourney #MedicalAdvancements #HealthAwareness #PharmacyLife #MedicalUpdates

Are GLP-1 drugs the future of diabetes treatment? Dive into the latest insights and trends in this MedCity News article. Discover what experts, like our own Nicole Bulochnik, are saying about the sustainability and impact of GLP-1 drugs on the healthcare industry. Click the link to learn more! #HealthCareInnovation #DiabetesTreatment #GLP1Drugs

How can the sustainability of Pressurised Metered Dose Inhalers be improved going into the future? Managing Consultant, Paul Hardman assesses in his whitepaper. https://bit.ly/3uRLXFb #inhalation #sustainability #pharmaceuticals

🌟 Tria Triumph: GLP-1’s are Not for Everyone! 🌟 A patient with diabetes and a history of a heart attack initially faced GI discomfort from metformin IR. After a change in medication to Ozempic, their GI symptoms worsened dramatically. The patient described the issues as “wicked” with severe gas, nausea, and diarrhea. Our Tria Health pharmacist stepped in, thoroughly investigating the timeline of symptoms and medication changes. By pinpointing Ozempic as the likely cause, the pharmacist recommended discontinuing it and returning to metformin, this time in the extended-release (ER) formulation. Today, the patient’s HgbA1C and blood glucose levels are at goal, thanks to careful medication management and personalized care. This case highlights the power of attentive pharmaceutical care in achieving optimal health outcomes. #GLP1 #PersonalizedCare #MedicationManagement

Our 'practice points' activity provides a comprehensive overview of oral antiviral therapy in COVID-19 management, complete with case studies for practical application. https://bit.ly/49dTopz #cpd #cme #meded #gp #covid19